Showing 1 - 10 of 334
premiums and out-of-pocket (OOP) copayments for prescriptions; we term the sum of these Consumer Inclusive Cost (CIC). We can … plans that are ex post optimal with respect to total cost (premiums and co-payments). Relative to the benchmark of a static …
Persistent link: https://www.econbiz.de/10009666978
With the Hatch-Waxman Act of 1984, the FDA included an unchallengeable exclusivity period for newly approved drugs, independent of patents. This potentially generates an incentive for firms to strategically delay the introduction of new versions (reformulations) of drugs until just before patent...
Persistent link: https://www.econbiz.de/10014135034
Markets require informed participants to function efficiently. This paper examines the impact of providing targeted information directly to patients on their purchasing-decisions regarding pharmaceutical drugs. We analyze the effect of informational letters sent by a Swiss health insurer to...
Persistent link: https://www.econbiz.de/10014564096
We analyze changes in the willingness to substitute from prescribed pharmaceuticals to more affordable generic equivalents in response to the first experience with a substitution. Using Swedish individual-level data of prescribed and dispensed pharmaceuticals, we employ a dynamic event study and...
Persistent link: https://www.econbiz.de/10013330007
This article examines the market power of branded prescription drugs faced with generic competition. Using prescription-level and matched socioeconomic panel data of the entire Swedish population between 2010 and 2016, I provide evidence for the key role of switching costs. A discontinuity...
Persistent link: https://www.econbiz.de/10012615385
We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R&D investments in new (differentiated) drugs, and thereby affect the probability distribution of future market structures in the industry. Within a fairly general model framework,...
Persistent link: https://www.econbiz.de/10003771873
The US and the EU recently introduced regulation to curb the extent of risky off-label drug use. It offers manufacturers a prolongation of patent protection or exclusivity if they invest in pediatric clinical tests. This paper shows that a reinforcement of physician liability for off-label use...
Persistent link: https://www.econbiz.de/10003847110
treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost …
Persistent link: https://www.econbiz.de/10003900791
Persistent link: https://www.econbiz.de/10003903146
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when...
Persistent link: https://www.econbiz.de/10003471161